New research indicates that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional lifestyle plans.
Published data in a major health publication shows that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments should be informed of the risk of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about 18 months.
Comparing Therapies
The research, which looked at 37 of trials involving over 9,000 of participants, compared the effects of these new drugs with older methods.
Scientists note that people who lose weight through dieting generally see a less rapid creep back—around 0.1 kg a month—once they finish.
Understanding the Fast Regain
Experts believe the mode of action of the jabs accounts for the accelerated regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is unsuppressed, making overeating a significant risk."
A Chronic Condition?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, given the significant potential of relapse, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who say that the results "highlight the long-term character of obesity," akin to managing diseases like hypertension.
User Accounts
Individuals who have come off the jabs describe a intense return of hunger.
"It felt as if a trigger activating and I was suddenly ravenous," recalled one woman.
This challenge is worsened if users have not established lasting lifestyle or habit modifications during therapy.
Significant Interest
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while the jabs are potent tools for weight loss, they are not a magic cure and long-term success likely depends on combined lifestyle support.
